Target intelligence / Profile preview

Epstein-Barr virus-derived peptide-HLA complexes (EBV peptide-HLA complexes)

Target
EBV peptide-HLA complexes
Molecular classification
Receptor, Other
01

Overview

Epstein-Barr virus (EBV)-derived peptide-HLA complexes represent a class of cell-surface antigens formed when intracellular EBV latent or lytic proteins are processed and presented by human leukocyte antigen (HLA) molecules. These complexes are crucial targets for the host immune system, particularly CD8+ and CD4+ T cells, which recognize them via T-cell receptors (TCRs) to initiate cytolytic clearance of infected cells. In EBV-associated malignancies—such as nasopharyngeal carcinoma, Hodgkin's lymphoma, Burkitt's lymphoma, gastric cancer, and post-transplant lymphoproliferative disease (PTLD)—tumor cells express specific EBV latent proteins (e.g., LMP1, LMP2, EBNA1, and the EBNA3 family) that are presented as peptide-HLA complexes. Therapeutic strategies targeting these complexes include TCR-engineered T-cell (TCR-T) therapies (such as YT-E001), TCR-like monoclonal antibodies (e.g., E1, L1, L2), bispecific antibodies, and peptide-selective chimeric antigen receptor (CAR) T cells (such as TÜ165). These agents mimic or utilize native TCR binding to selectively eliminate EBV-infected or malignant cells while sparing healthy tissue. However, clinical development is challenged by HLA restriction, potential cross-reactivity with self-peptides leading to off-tumor toxicity, and the immunosuppressive tumor microenvironment of solid tumors.

Other names
EBV peptide-MHC complexesEpstein-Barr virus peptide-HLA complexesEBV pMHC complexesEBV-derived peptide-MHC complexesEBV-LMP2/HLA complexesEBV-LMP1/HLA complexesEBNA/HLA complexes
02

Mechanism of action

Redirection of cytotoxic T lymphocytes or engineered immune cells to recognize and lyse cells presenting EBV-derived peptides on HLA molecules, or direct antibody-mediated targeting via TCR-like antibodies to induce complement-dependent or antibody-dependent cellular cytotoxicity.

03

Biological functions

Immune responseAntigen presentationT-cell activation
04

Disease associations

CancerInfectionInflammation
05

Safety considerations

On-target, off-tumor toxicityCytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)Graft-versus-host disease (GvHD)HLA downregulation or loss
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

HLA-A*02:01HLA-A*11:01HLA-A*24:02HLA-B*35HLA-DP5EBV DNA loadEBER expressionLMP1 expressionLMP2 expressionEBNA1 expression

Beyond the preview

Go deeper on Epstein-Barr virus-derived peptide-HLA complexes (EBV peptide-HLA complexes).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epstein-Barr virus-derived peptide-HLA complexes (EBV peptide-HLA complexes).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call